Safety & Efficacy of IR-101 in Relapsed/Refractory Neuroblastoma

NCT07067346 · Status: RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2025-07-29

No results posted yet for this study

Summary

Radiopharmaceutical in Relapsed/Refractory Neuroblastoma

Conditions

Interventions

DRUG

IR-101

IR-101 Dose Escalation

Sponsors & Collaborators

  • Sichuan University

    lead OTHER

Principal Investigators

  • Rong Tian, MD · West China Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
12 Months
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-07-18
Primary Completion
2026-06-30
Completion
2026-06-30

Countries

  • China

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07067346 on ClinicalTrials.gov